Inozyme Pharma (NASDAQ:INZY) Receives New Coverage from Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group initiated coverage on shares of Inozyme Pharma (NASDAQ:INZYGet Rating) in a research report issued on Thursday, The Fly reports. The brokerage set a “hold” rating on the stock.

A number of other research firms also recently weighed in on INZY. Needham & Company LLC began coverage on Inozyme Pharma in a report on Thursday, April 14th. They set a “buy” rating and a $23.00 price objective on the stock. Zacks Investment Research raised Inozyme Pharma from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Wednesday, May 18th. HC Wainwright began coverage on Inozyme Pharma in a report on Monday, February 7th. They set a “buy” rating and a $33.00 price objective on the stock. Finally, Wedbush decreased their price objective on Inozyme Pharma from $25.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $20.88.

Shares of NASDAQ:INZY opened at $4.00 on Thursday. The company has a market cap of $160.39 million, a P/E ratio of -1.52 and a beta of 1.12. The stock’s 50-day moving average is $4.27 and its 200-day moving average is $5.99. Inozyme Pharma has a 52-week low of $3.54 and a 52-week high of $19.58.

Inozyme Pharma (NASDAQ:INZYGet Rating) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.11. Research analysts predict that Inozyme Pharma will post -2.33 EPS for the current fiscal year.

In related news, Director Robert Lorne Hopfner acquired 1,070,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The stock was purchased at an average price of $3.69 per share, for a total transaction of $3,948,300.00. Following the transaction, the director now directly owns 2,661,154 shares of the company’s stock, valued at approximately $9,819,658.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Axel Bolte acquired 67,750 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The stock was bought at an average price of $3.69 per share, with a total value of $249,997.50. Following the transaction, the chief executive officer now directly owns 258,575 shares in the company, valued at $954,141.75. The disclosure for this purchase can be found here. Insiders bought 2,519,850 shares of company stock valued at $9,298,247 in the last quarter. 11.29% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of INZY. Suvretta Capital Management LLC raised its position in Inozyme Pharma by 170.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 986,400 shares of the company’s stock worth $11,432,000 after purchasing an additional 621,228 shares during the last quarter. Rock Springs Capital Management LP grew its holdings in Inozyme Pharma by 37.4% during the 1st quarter. Rock Springs Capital Management LP now owns 1,193,195 shares of the company’s stock worth $4,880,000 after acquiring an additional 324,729 shares during the period. BioImpact Capital LLC acquired a new stake in Inozyme Pharma during the 3rd quarter worth $3,717,000. Deerfield Management Company L.P. Series C grew its holdings in Inozyme Pharma by 7.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 2,344,786 shares of the company’s stock worth $27,176,000 after acquiring an additional 165,801 shares during the period. Finally, Caas Capital Management LP acquired a new stake in Inozyme Pharma during the 3rd quarter worth $1,569,000.

About Inozyme Pharma (Get Rating)

Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.

See Also

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.